Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 8/20 | 0.43 |
| ▸ | CTSK | P43235 | 7/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16970726 | 1.00 | ATM (0.49) | ATMCTSSCTSKABCB1CTSL | |
| SCHEMBL23877844 | 0.89 | ATM (0.46) | ATMCTSSCTSKABCB1CTSL | |
| SCHEMBL16970688 | 0.89 | ATM (0.46) | ATMCTSSCTSKABCB1CTSL | |
| SCHEMBL16970762 | 0.83 | ATM (0.41) | ATMCTSSCTSKABCB1CTSL | |
| SCHEMBL16979749 | 0.83 | FOLH1 (0.38) | ATMCTSSCTSKABCB1SYK | |
| SCHEMBL28113260 | 0.83 | ATM (0.68) | ATMCTSSCTSKABCB1CTSL | |
| SCHEMBL28113259 | 0.83 | ATM (0.68) | ATMCTSSCTSKABCB1CTSL | |
| SCHEMBL2953753 | 0.82 | ATM (0.47) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL18428003 | 0.80 | ATM (0.41) | ATMCTSSCTSKABCB1CTSL | |
| SCHEMBL28526998 | 0.80 | ATM (0.42) | ATMCTSSCTSKABCB1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102195-B1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES INC (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-106163509-B | β -substituted β -amino acids and analogs as chemotherapeutic agents | 夸德里加生物科学公司 | 2019-05-03 | — | — | CN | disclosed |
| US-10245246-B2 | β-substituted β-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| CN-106163509-A | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | 夸德里加生物科学公司 | 2016-11-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10245246-B2 | β-substituted β-amino acids and analogs as chemotherapeutic agents | SLC7A1, SLC3A2, SLC1A5 | ATM 3071/4885CTSS 3266/4885CTSK 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.